Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background Aberrant promoter hypermethylation is an epigenetic change that silences the expression of crucial genes, resulting in inactivation of the apoptotic pathway in various cancers. This hypermethylation can be restored by the demethylating agent 5-aza-2'-deoxycytidine (DAC). DAC might increase the tumor sensitivity to chemotherapy through demethylation and restoration of gene expression. We investigated the effect of combined therapy with DAC and irinotecan (CPT-11) on the human colon cancer cell line HCT-15.Methods Human colon cancer cell line HCT-15 was treated with DAC and/or CPT-11 both in vitro and in vivo. The changes in mRNA expression of several apoptosis-related genes were investigated by reverse transcriptase-polymerase chain reaction (PCR). Promoter methylation was detected by methylation-specific PCR and combined bisulfite restriction analysis. Suppression of tumor growth was observed during the treatment with DAC and/or CPT-11 and apoptosis in the tumors was investigated by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay.Results Promoter methylation of p14ARF, p16 INK4a, BNIP3, and XAF1 was confirmed, and DAC restored mRNA expression of these genes. Demethylation and restoration of gene expression was observed with low-dose DAC, and demethylation status was sustained for several weeks. Combined therapy with DAC and CPT-11 produced marked suppression in tumor growth compared with DAC or CPT-11 alone, both in vitro and in vivo.Conclusions Pretreatment with low-dose DAC may have the potential to be used as a "biosensitizer" of DNA-damaging agents such as CPT-11 when the apoptotic pathway is inactivated as a result of aberrant promoter methylation in the cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159,160,161].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [159]
Citations
Cites
1 retracted
Normand, G., Hemmati, P., Verdoodt, B., von Haefen, C., Wendt, J., Güner, D., May, E., Dörken, B., & Daniel, P. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412330200 · Cited by 56
RetractedMethylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 1×
“DAC traps the DNA methyltransferase enzyme in a covalent complex with the DNA, resulting in a loss of DNA methylation with each cycle of cell division.(14,15) Many studies demonstrated that treatment with DAC restored the expression and the functions of a number of crucial tumor suppressor genes such as p14 and suppre…”
BackgroundCOBRA: a sensitive and quantitative DNA methylation assay
Xiong, Z., & Laird, P. W. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.12.2532 · Cited by 1,195
Weitz, J., Koch, M., Debus, J., Höhler, T., Galle, P. R., & Büchler, M. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17706-x · Cited by 1,098
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Cited by
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159–161].”
Ikehata, M., Ogawa, M., Yamada, Y., Tanaka, S., Ueda, K., & Iwakawa, S. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00574 · Cited by 42
Metadata
- Authors
- Ishiguro, M., Iida, S., Uetake, H., Morita, S., Makino, H., Kato, K., Takagi, Y., Enomoto, M., & Sugihara, K.
- Affiliations
- Tokyo Medical and Dental University (JP)
- Corresponding author
- Ishiguro, Megumi
- Venue
- Annals of Surgical Oncology
- Published
- 2006-12-31
- Volume
- 14
- Issue
- 5
- Pages
- 1752-1762
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- OpenAlex
- W2004617245
- Cited by
- 43
- References
- 50
- Citations by year
- 2025: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 7
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Annals of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- decitabine, irinotecan, colon cancer, promoter hypermethylation, DNA demethylation, epigenetic silencing, apoptosis, p14ARF, p16INK4a, BNIP3, XAF1, combination chemotherapy, tumor growth inhibition
- MeSH terms
- Irinotecan, Decitabine, Animals, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Camptothecin, Colonic Neoplasms, Drug Therapy, Combination, Humans, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Nude, Neoplasm Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, RNA, Messenger, Gene Expression Regulation, Neoplastic, Survival Rate, Apoptosis, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p16, Reverse Transcriptase Polymerase Chain Reaction, In Situ Nick-End Labeling, Tumor Suppressor Protein p14ARF, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Cell Proliferation, Apoptosis Regulatory Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15. https://app.cochat.ai/papers/10.1245/s10434-006-9285-4
- The paper
- Ishiguro, M., Iida, S., Uetake, H., Morita, S., Makino, H., Kato, K., Takagi, Y., Enomoto, M., & Sugihara, K. (2007). Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-006-9285-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.